伊立替康联合卡培他滨治疗奥沙利铂化疗后进展的晚期结直肠癌的临床观察

Clinical observation of advanced colorectal cancer of irinotecan combined with capecitabine after treatment failure of chemotherapy by oxaliplatin

目的探讨伊立替康(艾力,CPT-11)联合卡培他滨(Xeloda)治疗奥沙利铂(OXA)化疗后进展的结直肠癌的临床疗效及安全性。方法以OXA化疗失败的32例晚期结直肠癌患者为研究对象,采用伊立替康联合卡培他滨方案治疗。伊立替康100mg/m2;卡培他滨2000mg/m2·d-1,每天2次口服,共14天;每三周重复一次。观察患者的疗效及不良反应。结果 32例患者中,完全缓解(CR)2例,部分缓解(PR)16例,有效率(RR)为56.3%。不良反应主要为Ⅰ～Ⅱ度骨髓抑制、恶心呕吐、腹泻、手足综合征。结论伊立替康联合卡培他滨治疗奥沙利铂化疗后进展的结直肠癌耐受性好且疗效满意。

Objective To observe effect and safety of advanced colorectal cancer of irinotecan combined with capecitabine after treatment failure of chemotherapy by oxaliplatin.Methods The 32 advanced colorectal cancer patients who OXA chemotherapy failed as the research object,CPT-11combined with Xeloda regimen were used,in particular：CPT-11 100mg/m2;Xeloda 2000mg/m2·d-1,2 times daily,altogether 14 days,every three weeks at a time.Observation the curative effect and adverse reaction of patients.Results In 32 cases,2 cases were CR,16cases were PR,RR were 56.25%,the main adverse reactions were Ⅰ-Ⅱ degree bone marrow depression,nausea and vomiting,diarrhea,hand-foot syndrome.Conclusions The curative effect of CPT-11 combined with Xeloda treatment after failure of chemotherapy with oxaliplatin in colorectal cancer is tolerated well and satisfactory.